Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 5/20 | 0.46 |
| ▸ | CAMK2A | Q9UQM7 | 1/20 | 0.39 |
| ▸ | OR51E2 | Q9H255 | 3/20 | 0.35 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.35 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.35 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | LDHA | P00338 | 1/20 | 0.33 |
| ▸ | SRR | Q9GZT4 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | ALKBH5 | Q6P6C2 | 1/20 | 0.33 |
| ▸ | SUCNR1 | Q9BXA5 | 1/20 | 0.33 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.31 |
| ▸ | GLRA1 | P23415 | 1/20 | 0.31 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ethylene Glycol SCHEMBL4958765 | 1.00 | TSHR (0.46) | TSHRCAMK2AOR51E2GPR84FFAR1 | |
| Ethylene Glycol SCHEMBL9313825 | 1.00 | — | — | |
| Ethylene Glycol SCHEMBL5133455 | 0.86 | — | — | |
| Ethylene Glycol SCHEMBL27514008 | 0.86 | TSHR (0.50) | TSHRCAMK2AGPR84FFAR1FFAR4 | |
| 1,4-Butanediol SCHEMBL5836779 | 0.84 | GPR84 (0.53) | TSHRCAMK2AOR51E2GPR84FFAR1 | |
| 1,4-Butanediol SCHEMBL9581258 | 0.84 | GPR84 (0.53) | TSHRCAMK2AOR51E2GPR84FFAR1 | |
| 1,6-Hexanediol SCHEMBL5836918 | 0.81 | GPR84 (0.58) | TSHRCAMK2AGPR84FFAR1FFAR4 | |
| Bicarbonate SCHEMBL9488228 | 0.80 | TSHR (0.56) | TSHRCAMK2AOR51E2GPR84FFAR1 | |
| Bicarbonate SCHEMBL310739 | 0.80 | — | — | |
| Bicarbonate SCHEMBL28880335 | 0.80 | TSHR (0.56) | TSHRCAMK2AOR51E2GPR84FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4721152-A2 | ORGANIC THIN FILM COATINGS FOR BATTERY MATERIALS | Coreshell Technologies, Inc. (US) | 2026-04-08 | — | — | EP | claimed |
| US-20250302760-A1 | BIODEGRADABLE, CONTROLLED RELEASE MICROCAPSULES | ENCAPSYS, LLC (US) | 2025-10-02 | — | — | US | claimed |
| WO-2024249841-A2 | ORGANIC THIN FILM COATINGS FOR BATTERY MATERIALS | CORESHELL TECHNOLOGIES, INC. (US) | 2024-12-05 | — | — | WO | claimed |
| EP-4721152-A2 | ORGANIC THIN FILM COATINGS FOR BATTERY MATERIALS | Coreshell Technologies, Inc. (US) | 2026-04-08 | — | — | EP | disclosed |
| US-20250302760-A1 | BIODEGRADABLE, CONTROLLED RELEASE MICROCAPSULES | ENCAPSYS, LLC (US) | 2025-10-02 | — | — | US | disclosed |
| WO-2024249841-A2 | ORGANIC THIN FILM COATINGS FOR BATTERY MATERIALS | CORESHELL TECHNOLOGIES, INC. (US) | 2024-12-05 | — | — | WO | disclosed |
| US-11951449-B2 | Method for preparing organic-inorganic hybrid microcapsule | LG HOUSEHOLD & HEALTH CARE LTD. (KR) | 2024-04-09 | — | — | US | disclosed |
| US-20230381327-A1 | REACTIVE CONJUGATES | DEBIOPHARM RESEARCH & MANUFACTURING S.A. (CH) | 2023-11-30 | — | — | US | disclosed |
| EP-4225378-A1 | REACTIVE CONJUGATES | Debiopharm Research & Manufacturing S.A. (CH) | 2023-08-16 | — | — | EP | disclosed |
| US-20230046947-A1 | REACTIVE CONJUGATES | DEBIOPHARM RESEARCH & MANUFACTURING S.A. (CH) | 2023-02-16 | — | — | US | disclosed |
| US-20230002706-A1 | NATURALLY DEGRADABLE MICROCAPSULES AND A METHOD OF PREPARING THE SAME | LG HOUSEHOLD & HEALTH CARE LTD. (KR) | 2023-01-05 | — | — | US | disclosed |
| WO-2012174580-A1 | HYBRID POLYMERIC MATERIALS FOR MEDICAL APPLICATIONS AND PREPARATION THEREOF | TECHNISCHE UNIVERSITÄT GRAZ (AT) | 2012-12-27 | — | — | WO | disclosed |
| EP-2537540-A1 | Hybrid polymeric materials for medical applications and preparation thereof | Technische Universität Graz (AT) | 2012-12-26 | — | — | EP | disclosed |
| US-7795440-B2 | N-substituted tricyclic 1-aminopyrazoles as inhibitors for the treatment of cell proliferative disorders | JANSSEN PHARMACEUTICA NV (BE) | 2010-09-14 | — | — | US | disclosed |
| EP-1506175-B1 | N-SUBSTITUTED TRICYCLIC 3-AMINOPYRAZOLES AS PDGF RECEPTOR INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2009-04-01 | — | — | EP | disclosed |
| US-20070142305-A1 | N-substituted tricyclic 1-aminopyrazoles as inhibitors for the treatment of cell proliferative disorders | HO CHIH Y | 2007-06-21 | — | — | US | disclosed |
| US-7196110-B2 | N-substituted tricyclic 3-aminopyrazoles as inhibitors for the treatment of cell proliferative disorders | JANSSEN PHAMACEUTICA N.V. (BE) | 2007-03-27 | — | — | US | disclosed |
| EP-1506175-A1 | N-SUBSTITUTED TRICYCLIC 3-AMINOPYRAZOLES AS PDGF RECEPTOR INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-02-16 | — | — | EP | disclosed |
| US-20040082639-A1 | N-substituted tricyclic 3-aminopyrazoles as inhibitors for the treatment of cell proliferative disorders | JANSSEN PHARMACEUTICA, N.V. (BE) | 2004-04-29 | — | — | US | disclosed |
| WO-2003097609-A1 | N-SUBSTITUTED TRICYCLIC 3-AMINOPYRAZOLES AS PDFG RECEPTOR INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2003-11-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230046947-A1 | REACTIVE CONJUGATES | FCGR3B, FCGR1A, FCGR2A | TSHR 510/4885CAMK2A 2699/4885OR51E2 4206/4885 |
| US-20070142305-A1 | N-substituted tricyclic 1-aminopyrazoles as inhibitors for the treatment of cell proliferative disorders | PDGFRA, PDGFRB, PDGFA | TSHR 1579/4885CAMK2A 700/4885OR51E2 4798/4885 |
| US-20040082639-A1 | N-substituted tricyclic 3-aminopyrazoles as inhibitors for the treatment of cell proliferative disorders | PDGFRA, PDGFRB, PDGFA | TSHR 1502/4885CAMK2A 686/4885OR51E2 4783/4885 |
| US-20230381327-A1 | REACTIVE CONJUGATES | FCGR3B, FCGR1A, FCGR2A | TSHR 526/4885CAMK2A 2572/4885OR51E2 4206/4885 |
| US-11951449-B2 | Method for preparing organic-inorganic hybrid microcapsule | INCENP, PHOSPHO1, CHMP4B | TSHR 4626/4885CAMK2A 1914/4885OR51E2 817/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.